TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07288320: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Epis

Sponsor: Neurocrine Biosciences · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 150 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$6,706,400

Rescue Site Savings

+$4,415,600

Unlock Full NCT07288320 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07288320 Rescue Dossier →